Evidence map›Paper›PMID 40269843›Full record

ArticleBMC complementary medicine and therapies2025

6-Gingerol, an active compound of ginger, attenuates NASH-HCC progression by reprogramming tumor-associated macrophage via the NOX2/Src/MAPK signaling pathway.

Qiurui Li, Meng Wang, Xuekuan Huang, Shang Wang, Chunli Li, Pan Li, Wei Xiang, Ling Yao, Chengdan Deng, Mingming Zhang and 1 more

Abstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qiurui LiCollege of Traditional Chinese Medicine, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China.
Meng WangCollege of Traditional Chinese Medicine, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China.
Xuekuan HuangCollege of Traditional Chinese Medicine, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China.
Shang WangCollege of Traditional Chinese Medicine, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China.
Chunli LiSchool of Basic Medical Science, Chongqing Medical University, Chongqing, China.
Pan LiCollege of Pharmacy, Chongqing Medical University, Chongqing, China.
Wei XiangChongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing University of Chinese Medicine, No. 61 Puguobao Road, Bishan District, Chongqing, 402760, China.
Ling YaoChongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing University of Chinese Medicine, No. 61 Puguobao Road, Bishan District, Chongqing, 402760, China.
Chengdan DengChongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing University of Chinese Medicine, No. 61 Puguobao Road, Bishan District, Chongqing, 402760, China.
Mingming ZhangChongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing University of Chinese Medicine, No. 61 Puguobao Road, Bishan District, Chongqing, 402760, China. zhangmm@cqmu.edu.cn.
Jianwei WangCollege of Traditional Chinese Medicine, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China. wjwcq68@163.com.

Funding

Chongqing Natural Science Foundation cstc2021jcyj-msxmX0320Chongqing traditional Chinese Medicine inheritance and Innovation team project 2023090006KJZX2022WJW008the National Natural Science Foundation of China NO.82104469the National Natural Science Foundation of China NO. 82274164
6 · The paper itself

Abstract

backgroundNon-alcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) accounts for an increasing proportion of HCC cases. Currently, effective pharmacological options for treating both NASH and NASH-HCC remain limited, necessitating the identification of novel therapeutic agents. Our previous studies have demonstrated that ginger can ameliorate nonalcoholic fatty liver disease (NAFLD) and prevent the occurrence of NASH. The therapeutic effects and underlying mechanisms of NASH-HCC, however, remain poorly understood.

methodsNetwork pharmacology, bioinformatics, single-cell RNA sequencing analysis, and molecular docking were used to identify the main active compounds, targets, and possible mechanisms of ginger in treating NASH-HCC. The anti-tumor efficacy and underlying mechanisms of the selected compound in treating NASH-HCC were validated through in vitro experimentation.

resultsNetwork pharmacology, bioinformatics, and molecular docking have revealed that 6-gingerol is the main active compound of ginger in treating NASH-HCC. SRC can be an essential target gene for ginger attenuating NASH-HCC progression, while the mitogen-activated protein kinase (MAPK) signaling pathway and reactive oxygen species (ROS) play equally important roles. Single-cell RNA sequencing of the HCC patients shows that the key targets of ginger in treating NASH-HCC are distributed in tumor-associated macrophage (TAMs). It has been reported that NOX2-derived ROS in macrophages can activate Src and then regulate downstream MAPK signaling cascades. 6-Gingerol can inhibit the proliferation, migration and reduce lipid deposition of liver cancer cells in vitro. More importantly, it induces polarization TAMs to M1 and enhances proinflammatory function, which may be achieved via the NOX2/Src/MAPK signaling pathway.

conclusionThis study proves that 6-gingerol, the primary active compound in ginger, plays a role in attenuating the progression of NASH-HCC by inhibiting the proliferation and migration of tumor cells, or reprogramming TAMs to the M1 phenotype via the NOX2/Src/MAPK signaling pathway and activating the TAM-mediated immune responses.

Indexed as

Carcinoma, HepatocellularCatecholsFatty AlcoholsLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseTumor-Associated MacrophagesZingiber officinaleAnimalsHumansMAP Kinase Signaling SystemMiceMolecular Docking SimulationNADPH Oxidase 2Signal TransductionCatecholsFatty AlcoholsgingerolNADPH Oxidase 26-GingerolMacrophage reprogrammingNASH-HCCTumor-associated macrophages

Identifiers

PMID40269843
PMCPMC12020160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.